Loading clinical trials...
Loading clinical trials...
A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments
Conditions
Interventions
TKI258
Locations
8
Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Matsuyama, Ehime, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Takatsuki, Osaka, Japan
Novartis Investigative Site
Sunto-gun, Shizuoka, Japan
Start Date
June 1, 2012
Primary Completion Date
September 1, 2013
Completion Date
September 1, 2013
Last Updated
February 27, 2017
NCT06885697
NCT06630130
NCT07035587
NCT01649271
NCT02310230
NCT06260150
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions